2:09 PM
 | 
Sep 15, 2017
 |  BC Week In Review  |  Company News  |  Deals

J&J drops Achillion HCV deal

Johnson & Johnson (NYSE:JNJ) terminated a 2015 deal with Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) to develop and commercialize HCV therapies, including triplet therapy JNJ-4178. J&J said it decided to discontinue development of JNJ-4178 “in light of the increasing availability of a number of highly effective therapies addressing the medical need in hepatitis...

Read the full 236 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >